TGR Biosciences Pty Ltd specializes in immunoassay technology, prominently featuring its patented CaptSure™ platform. This innovative antibody immobilization system enhances the speed, simplicity, and performance of various immunoassays. The CaptSure™ technology is versatile and supports multiplexing applications, allowing for the detection of multiple analytes simultaneously. It can be utilized across a range of formats, including bead-based assays, ELISA, lateral flow, immunohistochemistry, and microfluidics, making it suitable for both life sciences and diagnostics markets.

The company's flagship product, the AlphaLISA SureFire® Ultra™, is designed for high-throughput analysis of cell-based proteins using a no-wash, bead-based approach. This extensive assay range, which includes over 400 assays, is particularly valuable for pharmaceutical and biotech companies engaged in drug discovery research. TGR has also expanded its offerings to include SureFire® Ultra™ Multiplex, further enhancing the capabilities of its CaptSure™ technology. Additionally, TGR's CaptSure™ ELISA assay technology is integral to Abcam's SimpleStep ELISA range, providing a more efficient workflow compared to traditional methods.

Australia

TGR BioSciences is an Australian biotechnology
company, specializing in the development and manufacture
of immunoassays and immunoassay technologies.

TGR's CaptSure technology underpins its immunoassay products and is available for license.

TGR Biosciences Pty Ltd

Company Details